These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 24534758)

  • 1. Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry.
    Sørensen J; Hetland ML;
    Ann Rheum Dis; 2015 Mar; 74(3):e12. PubMed ID: 24534758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comment on 'Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry'.
    Feldtkeller E; Rudwaleit M
    Ann Rheum Dis; 2014 Dec; 73(12):e77. PubMed ID: 25252720
    [No Abstract]   [Full Text] [Related]  

  • 3. Discordance of Global Assessments by Patient and Physician Is Higher in Female than in Male Patients Regardless of the Physician's Sex: Data on Patients with Rheumatoid Arthritis, Axial Spondyloarthritis, and Psoriatic Arthritis from the DANBIO Registry.
    Lindström Egholm C; Krogh NS; Pincus T; Dreyer L; Ellingsen T; Glintborg B; Kowalski MR; Lorenzen T; Madsen OR; Nordin H; Rasmussen C; Hetland ML
    J Rheumatol; 2015 Oct; 42(10):1781-5. PubMed ID: 26233511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comment on: 'Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry' by Sørensen et al.
    Sykes M; Doll H; Gaffney K
    Ann Rheum Dis; 2014 Jul; 73(7):e44. PubMed ID: 24709862
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment Patterns with Disease-Modifying Antirheumatic Drugs in U.S. Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis.
    Walsh JA; Pei S; Penmetsa GK; Sauer BC; Patil V; Walker JH; Clewell J; Douglas KM; Clegg DO; Cannon GW; Halwani A
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1218-1228. PubMed ID: 31663467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry.
    Manara M; Caporali R; Favalli EG; Grosso V; Atzeni F; Sarzi Puttini P; Gorla R; Bazzani C; Fusaro E; Pellerito R; Rocchetta PA; Sinigaglia L
    Clin Exp Rheumatol; 2017; 35(5):804-809. PubMed ID: 28770712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioid use surrounding diagnosis and follow-up in patients with ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis: Results from US claims databases.
    Sheahan A; Anjohrin S; Suruki R; Stark JL; Sloan VS
    Clin Rheumatol; 2024 Jun; 43(6):1897-1907. PubMed ID: 38658403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry.
    Dreyer L; Magyari M; Laursen B; Cordtz R; Sellebjerg F; Locht H
    Ann Rheum Dis; 2016 Apr; 75(4):785-6. PubMed ID: 26698850
    [No Abstract]   [Full Text] [Related]  

  • 9. The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si.
    Rotar Ž; Tomšič M; Praprotnik S;
    Clin Rheumatol; 2019 Feb; 38(2):297-305. PubMed ID: 30324406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden.
    Kopp TI; Delcoigne B; Arkema EV; Jacobsen RK; Magyari M; Ibfelt EH; Locht H; Sellebjerg F; Cordtz RL; Jensen DV; Askling J; Dreyer L
    Ann Rheum Dis; 2020 May; 79(5):566-572. PubMed ID: 32161058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry.
    Glintborg B; Sørensen IJ; Loft AG; Lindegaard H; Linauskas A; Hendricks O; Hansen IMJ; Jensen DV; Manilo N; Espesen J; Klarlund M; Grydehøj J; Dieperink SS; Kristensen S; Olsen JS; Nordin H; Chrysidis S; Dalsgaard Pedersen D; Sørensen MV; Andersen LS; Grøn KL; Krogh NS; Pedersen L; Hetland ML;
    Ann Rheum Dis; 2017 Aug; 76(8):1426-1431. PubMed ID: 28473425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
    Ogdie A; de Vlam K; McInnes IB; Mease PJ; Baer P; Lukic T; Gruben D; Kwok K; Wang C; Hsu MA; Maniccia A
    RMD Open; 2020 Feb; 6(1):. PubMed ID: 32396519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
    Heiberg MS; Koldingsnes W; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
    Arthritis Rheum; 2008 Feb; 59(2):234-40. PubMed ID: 18240258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
    Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
    Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Screening for tuberculosis before TNFα treatment in routine rheumatic care in Iceland. Result from the nationwide ICEBIO registry].
    Bjorgulfsson TM; Gröndal G; Blondal T; Gudbjornsson B
    Laeknabladid; 2018 Mai; 104(5):231-235. PubMed ID: 29717989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany.
    Krüger K; Burmester GR; Wassenberg S; Bohl-Bühler M; Thomas MH
    Rheumatol Int; 2019 Jan; 39(1):131-140. PubMed ID: 30415451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden.
    Hellgren K; Smedby KE; Backlin C; Sundstrom C; Feltelius N; Eriksson JK; Baecklund E; Askling J
    Arthritis Rheumatol; 2014 May; 66(5):1282-90. PubMed ID: 24782185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L; Pope JE; Payne M
    J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of malignancy in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under immunosuppressive therapy: a single-center experience.
    Fantò M; Peragallo MS; Pietrosanti M; Di Rosa R; Picchianti Diamanti A; Salemi S; D'Amelio R
    Intern Emerg Med; 2016 Feb; 11(1):31-40. PubMed ID: 26099279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers.
    Hellgren K; Dreyer L; Arkema EV; Glintborg B; Jacobsson LT; Kristensen LE; Feltelius N; Hetland ML; Askling J;
    Ann Rheum Dis; 2017 Jan; 76(1):105-111. PubMed ID: 27147709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.